Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (86)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chan, E. Y.W.
Right arrow Articles by Olson, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, E. Y.W.
Right arrow Articles by Olson, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2002, Vol. 11, No. 17 1939-1951
© 2002 Oxford University Press

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease

Edmond Y.W. Chan1,{dagger}, Ruth Luthi-Carter2,{dagger}, Andrew Strand3, Steven M. Solano2, Sarah A. Hanson2, Molly M. DeJohn2, Charles Kooperberg3, Kathryn O. Chase4, Marian DiFiglia5, Anne B. Young2, Blair R. Leavitt1, Jang-Ho J. Cha2, Neil Aronin4, Michael R. Hayden1 and James M. Olson3,*

1Center for Molecular Medicine and Therapeutics, Department of Medical Genetics, Children's and Women's Hospital, University of British Columbia, Vancouver, British Columbia, Canada, V5H 4H4, 2Center for Aging, Genetics and Neurodegeneration, Massachusetts General Hospital, Charlestown, MA 02129-4404, USA, 3Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA, 4Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA and 5Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA

Received March 12, 2002; Accepted June 7, 2002

Both transcriptional dysregulation and proteolysis of mutant huntingtin (htt) are postulated to be important components of Huntington's disease (HD) pathogenesis. In previous studies, we demonstrated that transgenic mice that express short mutant htt fragments containing 171 or fewer N-terminal residues (R6/2 and N171-82Q mice) recapitulate many of the mRNA changes observed in human HD brain. To examine whether htt protein length influences the ability of its expanded polyglutamine domain to alter gene expression, we conducted mRNA profiling analyses of mice that express an extended N-terminal fragment (HD46, HD100; 964 amino acids) or full-length (YAC72; 3144 amino acids) mutant htt transprotein. Oligonucleotide microarray analyses of HD46 and YAC72 mice identified fewer differentially expressed mRNAs than were seen in transgenic mice expressing short N-terminal mutant htt fragments. Histologic analyses also detected limited changes in these mice (small decreases in adenosine A2a receptor mRNA and dopamine D2 receptor binding in HD100 animals; small increases in dopamine D1 receptor binding in HD46 and HD100 mice). Neither HD46 nor YAC72 mice exhibited altered mRNA levels similar to those observed previously in R6/2 mice, N171-82Q mice or human HD patients. These findings suggest that htt protein length influences the ability of an expanded polyglutamine domain to alter gene expression. Furthermore, our findings suggest that short N-terminal fragments of mutant htt might be responsible for the gene expression alterations observed in human HD brain.

{dagger} The authors wish it be known that, in their opinion the first two authors should be regarded as joint First Authors.

* To whom correspondence should be addressed at: Fred Hutchinson Cancer Research Center, D4-100, 1100 Fairview Ave N, Seattle, WA 98109, USA. Tel: +1 2066677955; Fax: +1 2066672917; Email: jolson{at}fhcrc.org


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
M.-C. Chiang, H.-M. Chen, H.-L. Lai, H.-W. Chen, S.-Y. Chou, C.-M. Chen, F.-J. Tsai, and Y. Chern
The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system
Hum. Mol. Genet., August 15, 2009; 18(16): 2929 - 2942.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
C. Zabel, L. Mao, B. Woodman, M. Rohe, M. A. Wacker, Y. Klare, A. Koppelstatter, G. Nebrich, O. Klein, S. Grams, et al.
A Large Number of Protein Expression Changes Occur Early in Life and Precede Phenotype Onset in a Mouse Model for Huntington Disease
Mol. Cell. Proteomics, April 1, 2009; 8(4): 720 - 734.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
Q. Fang, A. Strand, W. Law, V. M. Faca, M. P. Fitzgibbon, N. Hamel, B. Houle, X. Liu, D. H. May, G. Poschmann, et al.
Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease
Mol. Cell. Proteomics, March 1, 2009; 8(3): 451 - 466.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Kuhn, D. R. Goldstein, A. Hodges, A. D. Strand, T. Sengstag, C. Kooperberg, K. Becanovic, M. A. Pouladi, K. Sathasivam, J.-H. J. Cha, et al.
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage
Hum. Mol. Genet., August 1, 2007; 16(15): 1845 - 1861.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Haacke, F. U. Hartl, and P. Breuer
Calpain Inhibition Is Sufficient to Suppress Aggregation of Polyglutamine-expanded Ataxin-3
J. Biol. Chem., June 29, 2007; 282(26): 18851 - 18856.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
K. Tagawa, S. Marubuchi, M.-L. Qi, Y. Enokido, T. Tamura, R. Inagaki, M. Murata, I. Kanazawa, E. E. Wanker, and H. Okazawa
The Induction Levels of Heat Shock Protein 70 Differentiate the Vulnerabilities to Mutant Huntingtin among Neuronal Subtypes
J. Neurosci., January 24, 2007; 27(4): 868 - 880.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Cornett, L. Smith, M. Friedman, J.-Y. Shin, X.-J. Li, and S.-H. Li
Context-dependent Dysregulation of Transcription by Mutant Huntingtin
J. Biol. Chem., November 24, 2006; 281(47): 36198 - 36204.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. M. A. Oliveira, S. Chen, S. Almeida, R. Riley, J. Goncalves, C. R. Oliveira, M. R. Hayden, D. G. Nicholls, L. M. Ellerby, and A. C. Rego
Mitochondrial-Dependent Ca2+ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors
J. Neurosci., October 25, 2006; 26(43): 11174 - 11186.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Hodges, A. D. Strand, A. K. Aragaki, A. Kuhn, T. Sengstag, G. Hughes, L. A. Elliston, C. Hartog, D. R. Goldstein, D. Thu, et al.
Regional and cellular gene expression changes in human Huntington's disease brain
Hum. Mol. Genet., March 15, 2006; 15(6): 965 - 977.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
A. Pal, F. Severin, B. Lommer, A. Shevchenko, and M. Zerial
Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington's disease.
J. Cell Biol., February 13, 2006; 172(4): 605 - 618.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
B. L. Apostol, K. Illes, J. Pallos, L. Bodai, J. Wu, A. Strand, E. S. Schweitzer, J. M. Olson, A. Kazantsev, J. L. Marsh, et al.
Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity
Hum. Mol. Genet., January 15, 2006; 15(2): 273 - 285.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Iijima-Ando, P. Wu, E. A. Drier, K. Iijima, and J. C. P. Yin
cAMP-response element-binding protein and heat-shock protein 70 additively suppress polyglutamine-mediated toxicity in Drosophila
PNAS, July 19, 2005; 102(29): 10261 - 10266.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M.-C. Chiang, Y.-C. Lee, C.-L. Huang, and Y. Chern
cAMP-response Element-binding Protein Contributes to Suppression of the A2A Adenosine Receptor Promoter by Mutant Huntingtin with Expanded Polyglutamine Residues
J. Biol. Chem., April 8, 2005; 280(14): 14331 - 14340.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. J. Morton, N. I. Wood, M. H. Hastings, C. Hurelbrink, R. A. Barker, and E. S. Maywood
Disintegration of the Sleep-Wake Cycle and Circadian Timing in Huntington's Disease
J. Neurosci., January 5, 2005; 25(1): 157 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
Q. Ruan, M. Lesort, M. E. MacDonald, and G. V.W. Johnson
Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway
Hum. Mol. Genet., April 1, 2004; 13(7): 669 - 681.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
B. R. Jarabek, R. P. Yasuda, and B. B. Wolfe
Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model
Brain, March 1, 2004; 127(3): 505 - 516.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. L. Sugars, R. Brown, L. J. Cook, J. Swartz, and D. C. Rubinsztein
Decreased cAMP Response Element-mediated Transcription: AN EARLY EVENT IN EXON 1 AND FULL-LENGTH CELL MODELS OF HUNTINGTON'S DISEASE THAT CONTRIBUTES TO POLYGLUTAMINE PATHOGENESIS
J. Biol. Chem., February 6, 2004; 279(6): 4988 - 4999.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Michalik and C. Van Broeckhoven
Pathogenesis of polyglutamine disorders: aggregation revisited
Hum. Mol. Genet., October 15, 2003; 12(90002): R173 - 186.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Z.-X. Yu, S.-H. Li, J. Evans, A. Pillarisetti, H. Li, and X.-J. Li
Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease
J. Neurosci., March 15, 2003; 23(6): 2193 - 2202.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Holbert, A. Dedeoglu, S. Humbert, F. Saudou, R. J. Ferrante, and C. Neri
Cdc42-interacting protein 4 binds to huntingtin: Neuropathologic and biological evidence for a role in Huntington's disease
PNAS, March 4, 2003; 100(5): 2712 - 2717.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. D. Strand, J. M. Olson, and C. Kooperberg
Estimating the statistical significance of gene expression changes observed with oligonucleotide arrays
Hum. Mol. Genet., September 15, 2002; 11(19): 2207 - 2221.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
R. Luthi-Carter, A. D. Strand, S. A. Hanson, C. Kooperberg, G. Schilling, A. R. La Spada, D. E. Merry, A. B. Young, C. A. Ross, D. R. Borchelt, et al.
Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects
Hum. Mol. Genet., August 15, 2002; 11(17): 1927 - 1937.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.